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ABSTRACT 
Introduction: Food-drug interactions represent a growing concern for health services and are 
clinically significant. There is a lack of published studies in this area. In clinical practice, 
these interactions can cause problems for the patient, resulting in treatment failure, adverse 
reactions, and nutritional deficiency. However, the addition of a pharmacist to the 
multidisciplinary treatment team can improve the identification, prevention, and resolution of 
problems for the patients that involve drug interactions, as well as, food-drug interactions. 
Objective: To review the literature to identify the role with respect to patients’ education 
about food-drug interactions. Methods: The online database search was carried out in the 
following databases: Pubmed, Scopus, Lilacs, Scielo, and Ebsco in Januaruy, 2017. A new 
survey was carried out in January 2017 to update the search for articles. The descriptors were 
"patient education," "knowledge," "patient," "pharmacists," "counseling," "food-drug 
interaction," and "role," and these words were arranged in different combinations. Then, there 
were an evaluation of studies, in which the title, abstract, and full text of the studies were 
eligible. The review was written according to the PRISMA criterion (Preferred Reporting 
Items for Systematic reviews and Meta-Analyses). Results: The search identified 393 related 
articles, however, only four articles were eligible. The pharmacist's role in the care and 
guidance of patients is linked to the application of their skills such as optimizing drug therapy, 
decreasing unwanted adverse effects, therapeutic drug monitoring, adjusting medications 
based on organ function to the reduction of unfavorable occurrences caused by the 
interactions between drugs and food.  Thus, when the pharmacist is included as an active 
member of the healthcare team, problems related to food-drug interactions can be reduced and 
therefore have a large benefit for the patient. Conclusion: These studies revealed that the 
pharmacist has an important role in the detection, prevention, and resolution of problems 
related to the interaction between drugs and food. The pharmacist also can improve the 
patient's pharmacotherapy through the development of programs and methods that will help 
them in clinical practice.  
What is already known about this subject:  
There are few studies related to this subject, what shows the importance to develop more 
researches about it. The literature has shown that most articles reviewed involved only 
interactions between drugs, and failed to include the interactions between drugs and foods that 
usually occur, provoking unwanted effects such as: potentialization or reduction of the drug's 
efficacy.  
What this study adds:  
In this context of scarcity of published articles related to food-drug interaction, this study 
becomes relevant to show the importance of pharmacist's expertise, involvement and role in 
the counseling of patients about food-drug interactions in clinical practice.
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INTRODUCTION 
 
According to the WHO, more than 50% of the medicines are prescribed, dispensed, 
and administered incorrectly around the world.1The problems related to medications occur 
frequently in medical practice and are considered the main causes of health complications and 
economic and social losses.2,3,4 Among these problems, highlights the interaction between 
food and drugs. These interactions can be defined as events when food, or one of its 
components, interferes with the pharmacokinetic and pharmacodynamic parameters of 
medicines or when drugs affect the body’s nutritional balance.2  
An interaction is considered to be clinically significant if it alters therapeutic drug 
response or compromises nutrition status resulting in some degree of malnutrition. The 
clinical consequences of an interaction are related to alterations in the absorption and effect of 
the drug or nutrient.2 This could result in partial or total failure of the pharmacotherapy as 
well as significant adverse drug reactions (e.g., monoamine oxidase inhibitors increases high 
levels of tyramine in foods such as cheese, wine, and dairy products).3 In addition, drugs with 
a low therapeutic index (lithium, theophylline, and phenytoin) and dosages that require 
greater control (e.g., anticoagulants) tend to have more clinically significant food-drug 
interactions.4 
This type of interaction can be present in different cases and groups of patients. The 
elderly, obese, critically ill, transplant recipients, patients receiving enteral nutrition, and 
patients with chronic disease who use multiple medications, for example, can be considered 
high risk to have some food-drug or drug interactions.5,6 
According to above findings, the multidisciplinary team should be able to discuss the 
patients’ needs and provide information about their treatment and medicines in order to avoid 
possible complications and achieve therapeutic success.7,8 In such a team, the pharmacist 
should assist to identify medication challenges faced by patients, as well as assisting in 
preventing of potential issues associated with drug therapy, such as significant drug 
interactions (including food-drug interactions).9,10,11 
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Although the literature highlights the importance of the multiprofessional team and 
the pharmacist in the food-drug interaction, there have been few published studies that 
describe the role of the pharmacist that is linked to ensure the correct use of medications and 
food, besides counsel patients regarding this interaction. Therefore, the aim of this study was 
to identify the pharmacist's role in guiding to the patient with respect to food-drug 
interactions. 
 
METHODS 
 
This systematic review was carried out to identify and evaluate relevant studies’ 
main findings regarding the assessment of the pharmacist's role with respect to patients’ 
education about food-drug interactions. To this end, the following steps were performed: 
 
Identification and selection of studies:  
This study was a systematic review of publications from Pubmed, Scopus, Lilacs, 
Scielo, and Ebsco collected in January 2017. The descriptors used for the search were "patient 
education," "knowledge," "patient," "pharmacists," "counseling,” "food-drug interaction,"  
and “role” which were arranged in different combinations, according each database: “food-
drug interaction” AND pharmacists AND “patient education”; “food-drug interaction” AND 
pharmacists AND knowledge; “food-drug interaction” AND pharmacists AND patient; “food-
drug interaction” AND pharmacists AND counseling; “food-drug interaction” AND 
pharmacists AND role. 
Critical appraisal of the studies and data collection: 
The following screening process was conducted in three stages. (1) Articles were 
selected according to the relevance of their titles. (2) Abstracts were evaluated based on the 
pre-established inclusion criteria: original papers that discussed the interactions between 
medicines and food, patients’ knowledge, and the pharmacist's role in patient education. (3) 
Articles that met all inclusion criterias were carefully evaluated before initiating the data 
extraction process. 
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The excluded studies were those that were either not written in English, Portuguese, 
or Spanish, had no abstract or details of the methodology used in the research, or were articles 
that were systematic or literature reviews. Items that appeared in more than one database were 
considered only once. The analysis of the selected articles was performed by two independent 
reviewers, with disagreements resolved by consensus, and if necessary a consensus by a third 
investigator. 
The articles selected for the data extraction were examined based on the following 
variables: (a) geographical location and study setting, (b) type of study, (c) types and number 
of patients involved in the study, (d) elucidation of the pharmacists’ role and pharmaceutical 
knowledge, (e) tools that assisted in the evaluation of food-drug interactions, (f) interaction 
between pharmacists and other professionals, (g) drugs involved in the interactions with food, 
(h) pharmaceutical interventions for food-drug interactions, (i) results of pharmaceutical 
interventions, and (j) limitations. 
 
Evaluation of the methodological quality of the selected studies: 
 
 The methodological quality of the articles was evaluated according to the 
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) 
recommendations. 12 Two categories were established in this regard: (1) “yes” when the study 
met the STROBE criteria and (2) “no” when the STROBE criteria were not met. 
 
This review was written according to the PRISMA statement criterion (Preferred 
Reporting Items for Systematic reviews and Meta-Analyses), which provides essential 
information on the methodology and conduction of systematic reviews.3 
 
RESULTS 
From the five search databases mentioned previously, it was obtained a sample of 
393 articles, of which 24 articles were present in more than one database. Therefore, the total 
number of articles was 369, of which only 78 had relevant titles and were subsequently 
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submitted for further analysis of their abstracts (Figure 1). It is noteworthy that no relevant 
studies were found from the Scielo and Lilacs databases. 
After reading the abstracts, 29 articles were pre-selected for further evaluation of the 
full texts. Of these, 25 articles were excluded; 15 articles did not meet the inclusion criteria 
for the study, seven articles were systematic reviews, one article was a tutorial, one article 
was written in Japanese, and the full text of one article was not available. At the end of the 
selection process, only four articles13,14,15,16 were included in the sample: three were written in 
English and one in Spanish. 
With respect to the location of the studies, two studies were developed in the United 
States, one in Iran, and one in Argentina. All the studies were developed and carried out in a 
hospital setting. Thus, the target audience consisted of hospitalized patients, even with certain 
peculiarities. The number of patients and the type of study conducted were not reported by all 
the studies in this review. Table 1 describes the general characteristics of the articles that were 
included in this study. 
In the evaluation of specific aspects of the articles (Table 2), the pharmacist's role 
was found to be associated with clinical practice through assisting in the detection and 
evaluation of interactions between drugs and food in all the studies in the sample. Another 
important point showed that the need for the addition of a pharmacist to the multidisciplinary 
team was mentioned in all the articles in order to improve the clinical condition of patients. 
Additionally, the limitations of some of the studies are reported in Table 2. 
According to the STROBE Statement (Table 3), it could be verified the lack of a 
more precise and complete description of the studies involved in this review. Half of the 
studies (50%) did not describe the study design. None of them (0%) defined variables clearly, 
data source, bias, statistical methods and limitations, as also they did not discuss the 
generalization (external validity) of the study results. 
  
 
DISCUSSION 
Interactions between drugs and food can influence the success of therapy and 
treatment.17,18 This can even cause potential complications for patients, such as toxicity or 
adverse effects, therapeutic failure, and nutritional deficiency.18,19 Possibly, patients with 
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multiple diseases, renal or hepatic failure, patients with autoimmune diseases, newborns, and 
post-surgery patients are the most susceptible to these food-drug interactions because they 
make use of polypharmacy.20 Nowadays, the identification of drug interactions is one of the 
most relevant issues for pharmacovigilance.21  
In this review, two of the four studies on the pharmacist's role to instruct the patient 
about food-drug interactions were carried out in the United States. These results are probably 
due to the fact that the United States is one of the forerunners in the provision of clinical 
services associated with the development of new models of pharmaceutical practices.22,23 On 
the other hand, in some less developed countries, for a long time the pharmacist was seen 
solely as a supplier of drugs. However, the reality is changing and improving clinical services 
is becoming important in patient care. 24,25,26 Therefore, it is necessary that the pharmacist 
keeps the patient, not the drugs, as the main focus of their professional practice, thereby 
promoting patient care and providing guidance of medication use. 
Although the review only shows articles in a hospital environment, the food-drug 
interaction can occur at any scope (basic health unit, home ...), 52 and these patients need the 
guidance of the pharmacist. It is necessary to carry out studies in these other areas to verify 
the incidence of these interactions and how the pharmacist can avoid them. 
The fact that all the analyzed studies have been executed in hospitals, emphasizes the 
importance of a multidisciplinary team for treatment. According to Samartín et al. 2014, the 
integration of health professionals in hospitals allows for the combination of complementary 
skills and the supply of information necessary to achieve the best possible therapeutic results 
for the patient. Studies show that clinical services provided by pharmacists are important in 
different environments. In clinics, pharmacists improved the adherence and clinical outcomes 
in 53.5% of the patients with chronic disease, in contrast to 37.4% of the patients who were 
not subjected to pharmaceutical monitoring. In hospitals, the correct application of knowledge 
and practice in clinical pharmacy improved the clinical outcomes of ICU patients and reduced 
the cost of pharmacotherapy by 35.8%, in a study on anti-infectives and cardiovascular drugs 
in intensive care units.27,28,29  
In the multidisciplinary team, when pharmacists work along with doctors, nurses, and 
nutritionists, they can provide the best treatment for the patient by assessing the most 
appropriate pharmacotherapy which is both safe and effective, as well as by examining 
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possible interactions between drug and food. 20,21,30,31 Pharmacists can highlight and identify 
the needs of differentiated patients that suffer from asthma, chronic obstructive pulmonary 
disease, osteoporosis, hypertension, diabetes, or those who need enteral nutrition too. 
32,33,34,35,36,37,38,39 
Some studies that were reviewed included patients receiving enteral or parenteral 
nutrition, such as, bariatric patients and premature newborns.40,41The type of nutrition that 
these patients received, given through probes either inserted directly into the stomach or 
intestine of the patient or intravenously, required special attention for its preparation and 
administration. 42 In this context, the participation of the pharmacist is important not only for 
providing counsel to the health team, but also for the detection, prevention, and resolution of 
problems related to drug-drug interactions and food-drug interactions, envolving dosage form, 
stability problems, probe problems, necessity of time adjustment.43,44 
The study by Sánchez et al. (2006) corroborated the results of this study. They 
reported complications in 78.57% of the patients who used enteral nutrition and medicines 
concomitantly. 42 Therefore, the addition of a pharmacist to the multidisciplinary team could 
help indicate potential complications for patients and possible medication errors related to the 
administration of different drugs and nutrition can be minimized. 
All the articles that were analyzed elucidated the role of pharmacists and 
pharmaceutical knowledge to instruct the patient on the food-drug interaction. In addition, the 
strategies used to help orient patients to these interactions ranged from leaflets to mentoring 
programs and became important to monitor the occurrences of interactions, thereby ensuring 
patients’ safety. Studies have shown that the adoption of strategies developed by the 
pharmacist and/or healthcare team increases the probability of achieving therapeutic success 
and minimizes the risk of adverse food-drug interactions. 45,46,47,48,49  
In this study, the most professional relationship found was between pharmacists and 
nurses. Nurses are professionals who have direct patient contact and are therefore, able to 
overcome any problems related to these food-drug interactions. When nurses associate with 
the pharmacist, they can assess the problems related to food-drug interactions and help 
monitor the pharmacotherapy, for example, in establishing the appropriate times for drug 
administration.50 In short, we have found that communication and collaboration between the 
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members of the health care team is necessary to improve the effectiveness of 
pharmacotherapy with patients and reduce adverse events, as also healthcare costs. 51 
According to the STROBE recommendations, a lack of information regarding 
sampling may decrease the impact of the review. Therefore, researchers should describe the 
methods used to establish sample sizes in order to demonstrate increased robustness.53 
Besides, the included articles did not present a totality in any of the recommendations 
described by Strobe, which shows that the studies in this area did not appear well structured 
about the subject in question. 
This study had some limitations. The age and the clinical condition of the patients in 
the selected studies were not adequately described. Therefore, the results did not represent a 
homogeneous sample which consequently, prevented a better analysis of the food-drug 
interactions. Another limitation was that most articles did not contain a description of the type 
of studies carried out. In addition, the choice of descriptors may have restricted the results of 
this study. 
  
CONCLUSION 
In this review, it was noted that research on the pharmacist's role to instruct the patient 
on food-drug interactions was scarce. Moreover, it was observed that when the pharmacist 
works with other health professionals, they provide better therapeutic results because they 
reduce the occurrence of adverse food-drug interactions.  
In this review, we highlight the scarcity of published articles related to food-drug 
interactions, which indicates the need for more studies to be conducted in this field, especially 
in Brazil. Consequently, this review may be of help to researchers who want to understand 
and investigate this issue, and highlights one of the many important contributions that 
pharmacists add to clinical practice. 
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ANNEX 1 
 
Figure 1. Flowchart of progressive selection of studies according PRISMA (Preferred Reporting 
Items for Systematic reviews and Meta-Analyses). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ANNEX 2 
 
Exclusions based on the analysis of abstracts (n = 49): 
- Systematic reviews (5) 
- Did not show abstracts (9) 
- Did not focus on knowledge and pharmacist's role in 
patient education about the drug/food interaction (26) 
- Did not describe the methodology used in the research 
or didn't talk about knowledge (9) 
- Did not describe the methodology (1) 
 
 
 
 
Studies included 
(n = 4) 
 
 
Full articles selected - Studied 
Articles remainders (n = 369) 
Articles selected for evaluation of 
the full text (n = 29) 
Items excluded: Duplicates or triplicates 
(n = 24) 
 
 
 
 
 
 
 
 
Relevant titles to analysis of 
abstracts (n = 78) 
Potentially relevant publications found through 
the descriptors (n = 393) 
SCOPUS (283) 
EBSCO (73) 
PUBMED (37) 
 
 
 
Exclusion criteria (n = 25): 
- Full text unavailable (1); 
- Tutorial (1); 
- Systematic reviews (7); 
- Language was not included (1) 
- Did not involve the entire subject in study (15) 
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ANNEX 2 
 
Table 1. General characteristics of studies (n = 4) included in the systematic review  
 
NR = Not Reported  
 
 
Authors/Year 
 
Geographic location/Setting  
 
Study design 
 
Patient Type 
 
Number of patients  
 
Miller; Raatz, 1987 
 
 
United States/Hospital 
 
 
NR 
 
 
Patients hospitalized with a report of 
drug and food interactions 
 
 
NR 
 
Abbasi Nazari et al., 2010 Iran/Hospital Interventional research Patients hospitalized in four wards 
(gastrointestinal-liver; vascular surgery; 
endocrine and nephrology) 
      460 
Sánchez et al., 2006 
 
Argentina/Hospital 
 
Prospective study 
 
Patients admitted to hospital 
candidates to receive enteral nutrition 
 
 14 
 
 
Cerulli; Malone, 1999 
 
United States/Hospital NR Patients under the care of Clinical 
Nutrition Service and those receiving 
enteral or parenteral nutrition support 
  440 
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ANNEX 3 
 
Table 2. Specific characteristics of the articles (n=4) included in the systematic review  
  
Authors/ 
Year 
 
Role and 
knowledge 
of 
pharmacist 
reported 
Tools to aid in the evaluation of drug-food 
interaction 
Interaction of the 
pharmacist and other 
professionals 
(direct and indirect) 
Pharmacist 
intervention in these 
interactions 
(direct and indirect) 
Interventions's outcomes Limitations 
 
Miller; 
Raatz, 
1987 
 
 
 
 
 
 
 
YES 
 
 
Counseling program, involving 
Information sheets listing nutrients affected, 
foods to avoid, foods to 
emphasize and special 
comments on the nutritions-related 
effects of the medications 
 
 
Direct 
(pharmacists, 
physicians, dietitians and 
nurses) 
 
 
 
 
 
Direct 
 
 
A key factor in information 
development was maintenance 
of adequate nutrient intake 
as well as optimal drug therapy 
 
 
 
 
NR 
 
Abbasi 
Nazari et 
al., 2010 
YES 
Information pamphlets in which the 
guiding tables of drug and food usage were 
illustrated 
Direct 
(pharmacists and nurses) 
 
Indirect 
(The nurses' 
interventions were 
documented before 
and after a nurse 
education course 
supervised by a 
clinical pharmacist) 
Incorrect consumption rate of 
drug regarding food in the 
mentioned wards fell by 
13.1% after training the nurses; 
significant reduction of incorrect 
usage of drug 
 
There are few 
studies about 
the effect of 
nurse 
education in 
prevention or 
alleviation of 
drug-food 
interactions 
 
                                                                                                                                                                                                                                                         continued on next page 
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ANNEX 3 
 
Table 2. Specific characteristics of the articles included in the systematic review (continued) 
 
Authors/ 
Year 
 
Role and 
knowledge 
of 
pharmacist 
reported 
Tools to aid in the evaluation of 
drug-food interaction 
Interaction of the 
pharmacist and other 
professionals 
(direct and indirect) 
Pharmacist 
intervention in these 
interactions 
(direct and indirect) 
Interventions's outcomes Limitations 
Sánchez 
et al., 
2006 
 
YES 
 
Data collection form and a guide 
for drug delivery SNG. 
 
Direct 
(physicians specialist 
in endocrinology and 
nutrition, nursing staff 
and dietitians ) 
 
Direct 
 
The incorporation of the pharmacist 
in the nutritional support team 
helped to resolve problems in drug 
administration by nasogastric tube 
and in the evaluation and selection 
of the most appropriate enteral 
nutrition for each patient. 
 
There are not many 
studies on the 
pharmacotherapy 
accomplished by 
pharmacists in 
patients with enteral 
nutrition in hospitals. 
 
 
Cerulli; 
Malone, 
1999 
 
YES 
Medication administration sheets 
were developed and sent to the 
patient care unit with agents that 
need special administration by 
tube. 
 
 
Direct 
(physicians) 
 
Direct 
Drug costs were reduced;  
prevented and resolved problems 
related with drugs and improved 
therapeutic outcomes. 
 
NR 
NR = Not Reported                                                                                                                                                                                                                             
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ANNEX 4 
 
Table 3. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) 
recommendations and reported percentages of observational studies. 
 
 
Parts of 
article 
 
STROBE recommendations 
Reported 
percentage 
(No. 
reported/possible) 
Title Indicates the design of the study with terms commonly used in the title and 
abstract or only abstract 
0% (0/4) 
Abstract The abstract provides an informative and balanced summary of what was 
performed and what was found 
75% (3/4) 
Introduction 
Context/justification: Details the theoretical framework and the reasons for 
conducting the research 75% (3/4) 
Objectives: Presents specific objectives, including any pre-existent hypotheses. 75%(3/4) 
Methods Study design: Presents key elements regarding the study design at the beginning 
of the article 
50% (2/4) 
Scenario: Describes the practice setting and relevant places and dates, including 
the period of exposure, recruitment, follow-up, and data collection. 
75% (3/4) 
Participants: Cohort studies—describes inclusion criteria, data sources, and 
selection methods Cross-sectional studies—describes inclusion criteria, data 
sources, and participation selection method. 
75% (3/4) 
Variables—clearly defines all results, risks, indicators, potential confounding 
factors, and modifying effects 
0%(0/4) 
Data source/calculation—for each variable of interest, provides data sources and 
details on evaluation methods. Describes the evaluation of comparison methods 
0%(0/4) 
Bias—specifies all measures adopted to avoid potential sources of bias 0%(0/4) 
Study size—explains how the sample size was determined 25% (1/4) 
Statistical methods—describes all statistical methods, including those used for 
confounding factor control. 83.3 % (5/6) Describes all methods used to examine 
subgroups and interactions.  Explains the approach for missing data 
0%(0/4) 
Results Participants: Reports the number of participants in each stage of the study; for 
example, the numbers of patients that were potentially eligible participants, 
examined for eligibility, confirmed for eligibility, included in the study, in 
which follow-up was completed, and included in the analysis. Provides reasons 
for loss in each step. Considers the use of a flowchart. 
50% (2/4) 
Descriptive data: Describes the characteristics of the study participants and 
provides information on exposures and possible confounding factors. Indicates 
the number of participants with absent data for each variable of interest 
75% (3/4) 
Main results: Describes the unadjusted estimates and, if applicable, the adjusted 
estimates by confounding variables and their precision (for example, 95 % 
confidence intervals). Clarifies which confounding factors were adjusted and 
why they were included 
0% (0/4) 
Other analyses: Reports other analyses performed; for example, subgroups and 
interactions and sensitivity analyses 
0%(0/4) 
Discussion Main results: Summarizes the main results with reference to the study objectives 75% (3/4) 
Limitations: Discusses the study limitations, considering sources of potential 
bias or imprecision. Discusses the direction and magnitude of any potential bias 
0% (0/4) 
Interpretation: Presents a cautious interpretation of the results, considering the 
objectives, the limitations, the multiplicity of analyses, the results of similar 
studies, and other relevant evidence 
75% (3/4) 
Generalization: Discusses the generalization (external validity) of the study 
results 
0%(0/4) 
Support 0% (0/4) 
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